[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546551":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":43,"locations":50,"responsibleParty":70,"collaborators":73,"id":80,"slug":19,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":19,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":19,"enrollmentInfo":88,"targetDuration":19,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":52,"whyStopped":19,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Western University, Canada","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Virtual Weight Management Program","EXPERIMENTAL","A maximum tolerated dose of semaglutide (Ozempic\u002FWegovy) will be administered once weekly subcutaneously, up to a dose of 2.0 mg. Participants will also receive nutritional and movement advice, as well as virtual coaching once every 4 weeks for 6 months.",[13,14],"Drug: Semaglutide","Behavioral: Virtual Weight Management Coaching",{"label":16,"type":17,"description":18,"interventionNames":19},"Usual Care","NO_INTERVENTION","Usual care participants will continue to receive the typical standard of kidney and diabetes care. They will not receive any study medication or coaching.",null,[21,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Semaglutide","Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.",[9],[27,28,29],"GLP-1RA","Ozempic","Wegovy",{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":19},"BEHAVIORAL","Virtual Weight Management Coaching","Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.",[9],[36,40],{"name":37,"affiliation":38,"role":39},"Kristin K Clemens, MD, MSc","St. Joseph's Health Care London","PRINCIPAL_INVESTIGATOR",{"name":41,"affiliation":42,"role":39},"Louise Moist, MD, MSc","London Health Sciences Centre",[44],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},"Heather LaPier, BSc","CONTACT","519-646-6100","65373","heather.lapier@sjhc.london.on.ca",[51],{"facility":42,"status":52,"city":53,"state":54,"zip":55,"country":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","London","Ontario","N6A 5A5","Canada",{"type":58,"coordinates":59},"Point",[60,61],-81.23304,42.98339,{"lat":61,"lon":60},[64,65,67],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},{"name":66,"role":39,"phone":19,"phoneExt":19,"email":19},"Louise Moist, MD",{"name":68,"role":69,"phone":19,"phoneExt":19,"email":19},"Michael Chiu, MD","SUB_INVESTIGATOR",{"type":39,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Kristin Clemens","Associate Professor",[74,76,78],{"name":75,"class":6},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"name":77,"class":6},"Queen Elizabeth II Health Sciences Centre",{"name":79,"class":6},"Unity Health Toronto","100546551",false,"NCT06396416","Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2","Obesity Management for Kidney TRANSPLANTation: a Vanguard Study for an Innovative Randomized Controlled Trial, Embedded in Routine Care (OK-TRANSPLANT 2)","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* BMI; 35 kg\u002Fm\\^2\n* 10% risk of ESKD requiring renal replacement therapy over 2 years or receiving dialysis\n\nExclusion Criteria:\n\n* Known contraindication to a GLP-1RA (pancreatitis, personal or family history of medullary thyroid cancer, hypersensitivity)\n* Type 1 diabetes\n* No access to semaglutide via drug coverage\n* Pregnant, breastfeeding or planning to become pregnant\n* Currently in a GLP-1RA or GLP-1RA\u002FGIP study or planning to be in one","ALL","18 Years",{"count":89,"type":90},60,"ESTIMATED","INTERVENTIONAL",[93],"PHASE4","OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial.\n\nWe will randomize participants with obesity, high-risk CKD\u002Fdialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.",[96,97],"Obesity","Chronic Kidney Disease",[99,100,27,101,102,103],"Weight Management","Transplant","Pilot Study","Registries","Pragmatic","2026-06-24",{"date":106,"type":107},"2026-06-29","ACTUAL",{"date":109,"type":107},"2024-09-26",{"date":111,"type":90},"2026-12",{"name":5,"class":6},1]